Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$182.39
-0.1%
$194.66
$132.32
$212.71
$282.88B0.262.71 million shs17,710 shs
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$92.74
-0.3%
$96.58
$79.52
$124.00
$23.49B1.361.08 million shs8,841 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.38
+0.4%
$1.42
$1.03
$2.98
$95.48M1.431.67 million shs286,936 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$221.64
-0.4%
$237.59
$146.12
$251.71
$533.41B0.278.40 million shs4,588 shs
Moderna, Inc. stock logo
MRNA
Moderna
$50.30
+3.6%
$51.70
$22.28
$59.55
$19.96B1.059.47 million shs107,681 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.89
-2.2%
$27.14
$21.97
$28.75
$147.59B0.3542.49 million shs610,258 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
-1.24%-2.63%-8.99%-5.37%+30.35%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-2.35%-10.08%+3.79%-12.76%+0.24%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+10.48%+22.32%+30.48%-17.47%-22.16%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.93%-3.38%-6.75%-7.46%+41.43%
Moderna, Inc. stock logo
MRNA
Moderna
-0.51%+5.66%-3.13%+18.36%+101.75%
Pfizer Inc. stock logo
PFE
Pfizer
-0.12%-1.00%-2.28%-2.80%+16.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$182.39
-0.1%
$194.66
$132.32
$212.71
$282.88B0.262.71 million shs17,710 shs
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$92.74
-0.3%
$96.58
$79.52
$124.00
$23.49B1.361.08 million shs8,841 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.38
+0.4%
$1.42
$1.03
$2.98
$95.48M1.431.67 million shs286,936 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$221.64
-0.4%
$237.59
$146.12
$251.71
$533.41B0.278.40 million shs4,588 shs
Moderna, Inc. stock logo
MRNA
Moderna
$50.30
+3.6%
$51.70
$22.28
$59.55
$19.96B1.059.47 million shs107,681 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.89
-2.2%
$27.14
$21.97
$28.75
$147.59B0.3542.49 million shs610,258 shs
The 7 Hottest IPOs On Wall Street’s 2026 Watchlist Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
-1.24%-2.63%-8.99%-5.37%+30.35%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-2.35%-10.08%+3.79%-12.76%+0.24%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
+10.48%+22.32%+30.48%-17.47%-22.16%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.93%-3.38%-6.75%-7.46%+41.43%
Moderna, Inc. stock logo
MRNA
Moderna
-0.51%+5.66%-3.13%+18.36%+101.75%
Pfizer Inc. stock logo
PFE
Pfizer
-0.12%-1.00%-2.28%-2.80%+16.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.85
Moderate Buy$205.3312.58% Upside
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.72
Moderate Buy$131.6041.91% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.38
Hold$6.75390.91% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.67
Moderate Buy$252.4813.92% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-28.96% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.7410.99% Upside

Current Analyst Ratings Breakdown

Latest JNJ, MRNA, PFE, AZN, INO, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
DowngradeSell (D-)Sell (E+)
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
5/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetBuy$171.00 ➝ $158.00
5/6/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetOverweight$150.00 ➝ $140.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/4/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$33.00
4/30/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingBuy
4/30/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Reiterated RatingSell
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astrazeneca Plc stock logo
AZN
Astrazeneca
$58.74B4.82$12.75 per share14.30$30.55 per share5.97
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B7.22$1.30 per share71.35$86.54 per share1.07
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$60K1,591.33N/AN/A$0.36 per share3.82
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B5.66$13.93 per share15.91$33.73 per share6.57
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B10.27N/AN/A$18.67 per share2.69
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.36$4.29 per share6.03$15.86 per share1.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$6.6627.3915.851.5217.19%30.86%12.68%7/27/2026 (Estimated)
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$5.24N/AN/AN/A-44.39%-5.30%-4.62%N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$84.95M-$1.68N/AN/AN/AN/A-259.70%-83.46%5/13/2026 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6525.6217.622.2021.83%32.60%13.29%7/15/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.779.05N/A11.83%19.44%8.41%N/A

Latest JNJ, MRNA, PFE, AZN, INO, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.30N/AN/AN/A$0.33 millionN/A
5/5/2026Q1 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.59 million
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/29/2026Q1 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.52$2.58+$0.06$0.9850$14.93 billion$15.29 billion
4/14/2026Q1 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion
3/12/2026Q4 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.37$0.31+$0.68$0.31$0.33 millionN/A
2/14/2026Q4 2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/A-$0.3870N/A-$1.47N/A$1.06 billion
2/13/2026Q4 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.79-$2.11+$0.68-$2.11$611.14 million$678.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.38%+2.30%65.17%N/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.35%+5.25%60.12%64 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.64%-13.20%131.30%16 Years

Latest JNJ, MRNA, PFE, AZN, INO, and BNTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.64%5/8/20265/8/20266/12/2026
4/14/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.23%5/26/20265/26/20266/9/2026
2/10/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$1.59501.56%2/20/20262/20/20263/23/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.52
0.91
0.71
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.80
7.49
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
1.40
1.40
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.46
1.03
0.77
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.87

Institutional Ownership

CompanyInstitutional Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
1.70%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AN/A
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32069.44 million68.26 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.65 billionOptionable

Recent News About These Companies

Pfizer (PFE) Receives a Buy from Scotiabank
Pfizer Sees Unusually High Options Volume (NYSE:PFE)
Pfizer Inc. $PFE Shares Purchased by Swedbank AB
Pfizer’s newer medicines carry more weight in Q1
Pfizer Inc. (NYSE:PFE) Q1 2026 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Astrazeneca stock logo

Astrazeneca NYSE:AZN

$182.39 -0.13 (-0.07%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

BioNTech stock logo

BioNTech NASDAQ:BNTX

$92.74 -0.28 (-0.31%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.38 +0.01 (+0.36%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$221.64 -0.88 (-0.39%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$50.30 +1.76 (+3.62%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer stock logo

Pfizer NYSE:PFE

$25.89 -0.59 (-2.22%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.